(lp0
S'Galectin Therapeutics to Present at BIO CEO &amp; Investor Conference GlobeNewswire  - Feb 8, 2017 NORCROSS, Ga., Feb. 08, 2017  -- Galectin Therapeutics Inc. , the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.Small Cap Galectin Therapeutics is Sending Bullish Messages - SmallCap NetworkGalectin Therapeutics Inc  Stock Technicals at Critical ... - CML News'
p1
aS"Why Galectin Therapeutics Just Lost Nearly Half Its Market Cap Benzinga - Sep 28, 2016 Shares of Galectin Therapeutics Inc , a clinical-stage biopharmaceutical company that creates therapies for fibrotic disease and cancer, tumbled nearly 50 percent on Wednesday after the company said that a Phase 2a study called NASH-FX&nbsp;...Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot ... - GlobeNewswire Stock Update : Here's Why Galectin Therapeutics Inc Shares Are ... - Smarter Analyst"
p2
aS'Galectin Therapeutics Inc  Is An Alternative Catalyst Play Insider Financial - Feb 16, 2017 Galectin Therapeutics Inc  is drawing some considerable volume at the moment, and the company is up more than 45% this week alone as a result.Trading Covered Calls: Galectin Therapeutics Inc  : A Clever ... - CML News'
p3
aS'Galectin Therapeutics to Present at 29th Annual ROTH Conference GlobeNewswire  - Mar 9, 2017 NORCROSS, Ga., March 09, 2017  -- Galectin Therapeutics Inc. , the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.The Analysts Anticipate Galectin Therapeutics Inc  to Post ($0.17 ... - DailyQuint'
p4
aS'A Major Catalyst Awaits Galectin Therapeutics Next Week Seeking Alpha - Sep 23, 2016 Galectin Therapeutics  is a micro biotechnology company  focused on targeting galectin proteins.Two Speculative NASH Allocations Post Allergan plc Ordinary Shares (NYSE:AGN ... - Market Exclusive'
p5
aS'Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH ... GlobeNewswire  - Feb 1, 2017 NORCROSS, Ga., Feb. 01, 2017  -- Galectin Therapeutics Inc. , the leading developer of therapeutics that target galectin proteins, today announced it has generated sufficient financing to cover currently planned&nbsp;...'
p6
aS'Galectin Therapeutics Announces $4 Million in New Equity Financings GlobeNewswire  - Dec 29, 2016 NORCROSS, Ga., Dec. 29, 2016  -- Galectin Therapeutics Inc. , the leading developer of therapeutics that target galectin proteins, today announced it has recently completed a private placement of its common stock,&nbsp;...GALECTIN THERAPEUTICS INC.  Files An 8-K Entry into a Material ... - Market Exclusive'
p7
aS'Tobira 2.0  Could Galectin Therapeutics Inc  Be the Next Tobira? Street Register - Mar 14, 2017 There is a race to be first to market with a viable treatment and Galectin Therapeutics Inc  with its galectin inhibitors is a prime candidate.GALECTIN THERAPEUTICS INC.  Files An 8-K Regulation FD Disclosure - Market ExclusiveGalectin Therapeutics, Inc.  held by 21 SEC 13F Filers - Post Analyst'
p8
aS"Galectin Therapeutics and Aratana Therapeutics Look Forward to the 4th Quarter ... Yahoo Finance - Mar 15, 2017 A positive result from a small scale study on Galectin Therapeutics GR-MD-02 drug caused a 3.3 percent increase in the company's stock price, up 6 cents to $1.87 a share. The GR-MD-02 drug is designed to target the galectin-3 protein which plays a ..."
p9
aS'Galectin Therapeutics Reports Third Quarter 2016 Financial Results and ... GlobeNewswire  - Nov 8, 2016 NORCROSS, Ga., Nov. 08, 2016  -- Galectin Therapeutics Inc. , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three and nine months&nbsp;...'
p10
a.